There is no such thing as which one is more effective, Anrotinib or Bevacizumab, it mainly depends on which drug is suitable for the patient. Anrotinib and bevacizumab are both targeted therapeutic drugs, in which Anrotinib belongs to anti-angiogenic drugs, which directly acts on the tumor target to inhibit angiogenesis, blocking the blood and nutrient supply to the tumor, so as to gradually make the tumor shrink and atrophy, and help to stabilize the condition, and it can be used in the treatment of small-cell lung cancer, soft-tissue sarcoma, non-small-cell lung cancer and other diseases. Bevacizumab is also able to reduce the growth of tumor blood vessels and block its biological activity at the same time, so as to play an anti-tumor effect, which is mostly used in the treatment of metastatic colorectal cancer, advanced, metastatic or recurrent non-small cell lung cancer. Different patients have different types and genetic conditions, so the suitable drugs are also different, and it is necessary to choose the suitable drugs with the specific situation, there is no absolute good or bad. Drugs need to be taken under the guidance of professional doctors or clinical pharmacists.